- The weight loss jab Wegovy (semaglutide) has been approved for prescription in the UK to help reduce the risk of major cardiovascular events in overweight and obese patients with certain heart conditions.
- Experts have hailed the decision by the National Institute for Health and Care Excellence (NICE) as a significant step in combating obesity and improving patient outcomes.
- The drug can now be prescribed for both weight loss and to mitigate the risk of heart attacks and strokes, offering a dual benefit for patients.
- Academics caution that while beneficial, GLP-1 receptor agonist drugs like semaglutide can reduce muscle mass alongside fat, necessitating physical activity such as resistance training.
- Concerns have been raised about ensuring equitable access across the NHS to avoid a 'postcode lottery' in care when the drug is rolled out in the summer, and the need for adequate resource allocation.
IN FULL
